Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Deferred Taxes (2016 - 2025)

Ptc Therapeutics has reported Deferred Taxes over the past 5 years, most recently at $1000.0 for Q4 2025.

  • Quarterly results put Deferred Taxes at $1000.0 for Q4 2025, up 100.0% from a year ago — trailing twelve months through Dec 2025 was -$55.9 million (changed 0.0% YoY), and the annual figure for FY2025 was -$3000.0, up 99.99%.
  • Deferred Taxes for Q4 2025 was $1000.0 at Ptc Therapeutics, down from $2000.0 in the prior quarter.
  • Over the last five years, Deferred Taxes for PTCT hit a ceiling of $4.0 million in Q4 2023 and a floor of -$55.9 million in Q4 2024.
  • Median Deferred Taxes over the past 3 years was -$1500.0 (2023), compared with a mean of -$10.3 million.
  • Biggest five-year swings in Deferred Taxes: plummeted 1505.13% in 2024 and later soared 300.0% in 2025.
  • Ptc Therapeutics' Deferred Taxes stood at $4.0 million in 2023, then plummeted by 1505.13% to -$55.9 million in 2024, then skyrocketed by 100.0% to $1000.0 in 2025.
  • The last three reported values for Deferred Taxes were $1000.0 (Q4 2025), $2000.0 (Q1 2025), and -$55.9 million (Q4 2024) per Business Quant data.